Sodium-glucose co-transporter 2 inhibitors and erythrocytosis: a review

Authors

  • Najeeb Shah Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull and Hull University Teaching Hospitals NHS trust, Hull
  • Thushari Bandara Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull
  • Harshal Deshmukh Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull and Hull University Teaching Hospitals NHS trust, Hull
  • Lucy Batten Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull and Hull University Teaching Hospitals NHS trust, Hull
  • Chris Walton Hull University Teaching Hospitals NHS trust, Hull
  • Thozhukat Sathyapalan Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull and Hull University Teaching Hospitals NHS trust, Hull

DOI:

https://doi.org/10.15277/bjd.2022.384

Keywords:

type 2 diabetes mellitus, sodium-glucose co-transporter 2 inhibitors, erythrocytosis, haematocrit, polycythaemia

Abstract

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a class of anti-hyperglycaemic agents widely used in the treatment of type 2 diabetes mellitus (T2DM). They function by reducing renal glucose reabsorption and thereby promote urinary glucose excretion, resulting in improvement in glycaemic control. In large-scale clinical trials, SGLT2i have been shown to reduce cardiovascular mortality, non-fatal myocardial infarction and stroke significantly. In addition, clinical evidence suggests that they are renal protective as their use reduces the relative risk of end-stage renal disease and death from renal causes. These positive results have led to a rapid uptake of SGLT2i in clinical practice. Recently, clinical studies and case reports have suggested a link between SGLT2i therapy and erythrocytosis. The authors discuss possible mechanisms at cellular level that may cause erythrocytosis and explore its clinical relevance in people living with T2DM who are taking SGLT2i therapy.

Author Biography

Najeeb Shah, Department of Academic Diabetes, Endocrinology and Metabolism, Allam Diabetes Centre, Hull York Medical School, University of Hull, Hull and Hull University Teaching Hospitals NHS trust, Hull

I am Dr Najeeb Shah, a speciality trainee in Diabetes & Endocrinology in the Yorkshire & Humber Deanery and currently doing my MD from the University of Hull. I am the first author of this article.

References

Tang H, Fang Z, Wang T, Cui W, Zhai S, Song Y. Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus. Am J Car- diol 2016;118(11):1774-80. https://doi.org/10.1016/j/amjcard.2016.08.061

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New Engl J Med 2019;380(24):2295- 306. https://doi.org/10.1056/NEJMoa1811744

National institute for Health and Care Excellence. Type 2 diabetes in adults: management 2022 [updated 29 June 2022]. Available from: https://www.nice.org.uk/guidance/ng28.

Donnan K, Segar L. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 2019;846:23-9. https://doi.org/10.1016/j.ejphar.2019.01.002

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22): 2117- 28. https://doi.org/10.1056/NEJMoa1504720

Pittampalli S, Upadyayula S, Mekala HM, Lippmann S. Risks vs Benefits for SGLT2 Inhibitor Medications. Fed Pract 2018;35(7):45-8.

Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease--the Framingham study: a 34-year follow-up. Am Heart J 1994;127(3):674-82. https://doi.org/10.1016/0002-8703(94)90679-3

Maruyama T, Takashima H, Oguma H, et al. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. Diabetes Technol Ther 2019;21(12):713-20. https://doi.org/10.1089/dia.2019.0212

Yamada T, Sakaguchi K, Okada Y, et al. Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation. Diabetol Int 2021;12(2):197-206.

Mazer CD, Hare GMT, Connelly PW, et al. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation 2020; 141(8):704-07. https://doi.org/10.1161/CIRCULATIONAHA.119.044235

Aberle J, Menzen M, Schmid SM, et al. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Sci Rep 2020;10(1):22396-8. https://doi.org/10.1038/s41598-020-78734-2

Wang X, Fu R, Liu H, Ma Y, Qiu X, Dong Z. The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 2021; 10(6):6467-81. https://doi.org/10.21037/apm-21-1022

Tian Q, Guo K, Deng J, Zhong Y, Yang L. Effects of SGLT2 inhibitors on haematocrit and haemoglobin levels and the associated cardiorenal benefits in T2DM patients: A meta-analysis. J Cell Mol Med 2022;26(2):540-7. https://doi.org/10.1111/jcmm.17115

Shah N, Abdalla MA, Deshmukh H, Sathyapalan T. Therapeutics for type-2 diabetes mellitus: a glance at the recent inclusions and novel agents under development for use in clinical practice. Ther Adv Endocrinol Metab 2021; 12:20420188211042145. https://doi.org/10.1117/20420188211042145

Watson S. Erythrocytosis 2018 [Available from: https://www.healthline.com/health/erythrocytosis.

Kishimoto S, Maruhashi T, Kajikawa M, et al. Hematocrit, hemoglobin and red blood cells are associated with vascular function and vascular structure in men. Sci Rep 2020;10(1):11467. https://doi.org/10.1038/s41598-020- 68319-1

O'Leary MF. Hematocrit 2022 [Available from: https://emedicine.medscape.com/article/2054320-overview?ecd=ppc_google_rlsa-traf_mscp_ref_md_englang-uk-int&gclid=Cj0KCQjw48OaBhDWARIsAMd966B4C803At4sn-oPQ9lOTZqqxE0AAl_H3tY7pEinwrpMlxYwbrwoQD4aArNMEALw_wcB&icd=ssl_login_success_221020#a1.

Gašperšič J, Kristan A, Kunej T, Zupan IP, Debeljak N. Erythrocytosis: genes and pathways involved in disease development. Blood Transfus 2021; 19(6):518-32. https://doi.org/10.2450/2020.0197-20

Sano M, Goto S. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation 2019;139(17):1985-7. https://doi.org/10.1161/CIRCULATIONAHA.118.038881

Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased Hematocrit During Sodium- Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J Clin Med Res 2016;8(12): 844-7. https://doi.org/10.14740/jocmr2760w

Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4(5):411-19. https://doi.org/10.1016/S2213-8587(16)00052-8

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373(22): 2117-28. https://doi.org/10.1056/NEJMoa1504720

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013;15(9):853-62. https://doi.org/10.1111/dom.12127

O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 2015;309(3):F227-34. https://doi.org/10.1152/ajprenal.00689.2014

Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013;339(6116):211-4. https://doi.org/10.1126/science.1227166

Gotoh S, Hata J, Ninomiya T, et al. Hematocrit and the risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis 2015;242(1):199-204. https://doi.org/10.1016/j.atherosclerosis.2015.07014

Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with non- insulin-dependent diabetes mellitus. Ann Hematol 2006;85(2):79-85. https://doi.org/10.1007/s00277-005-1102-9

Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol 2021;83:503-28. https://doi.org/10.1146/an-nurev-physiol-031620-095920

Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci 2020;5(6):632-44. https://doi.org/10.1016/j.jacbts.2020.02.004

Wakabayashi S, Hisamitsu T, Nakamura TY. Regulation of the cardiac Na+/H+ exchanger in health and disease. J Molec Cell Cardiol 2013;61:68-76. https://doi.org/10.1016/j.yjmcc.201.02.007

Das L, Bhansali A, Walia R. Unmasking and aggravation of polycythemia vera by canagliflozin. Diabet Med 2018;35(11):1613-6. https://doi.org/10.1111/dme.13706

Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J 2016;37(19):1526- 34. https://doi.org/10.1093/eurheartj/ehv728

Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 2018;61(10):2108-17. https://doi.org/10.1007/s00125-018-4670-7

Chin-Yee B, Solh Z, Hsia C. Erythrocytosis induced by sodium-glucose co- transporter-2 inhibitors. CMAJ 2020;192(42):E1271-E. https://doi.org/10.1503/cmaj.76686

Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A. Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases. Diabetes Res Clin Pract 2020;162:108127. https://doi.org/10.1016/j.diabres.2020.108127

Motta G, Zavattaro M, Romeo F, Lanfranco F, Broglio F. Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases. J Clin Endocrinol Metab 2019;104(3):819-22. https://doi.org/10.1210/jc.2018-01702

Mithoowani S, Laureano M, Crowther MA, Hillis CM. Investigation and management of erythrocytosis. CMAJ 2020;192(32):E913-E8. https://doi.org/10.1503/cmaj.191587

Teo YH, Teo YN, Syn NL, et al. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta‐Analysis of Randomized‐Controlled Trials. J Am Heart Association 2021; 10(5):e019463. https://doi.org/10.1161/JAHA.120.019463

Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clinical Kidney Journal 2020;13(5):728-33. https://doi.org/10.1093/ckj/sfaa198

Downloads

Published

2022-12-21

Issue

Vol. 22 No. 2 (2022): December 2022

Section

Reviews

License

Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.